GAO to Review TrumpRx Savings Claim

The White House claims that Americans have saved over $700 million on medicines through TrumpRx.gov since its launch in February. Now the top Democrat on the House Energy and Commerce Committee wants the Government Accountability Office (GAO) to check whether that number holds up.

In an Oct. 27 letter, Rep. Frank Pallone Jr. of New Jersey asked GAO to examine how the platform tracks usage and whether its savings can be measured at all. “I request that GAO analyze whether and how the platform tracks usage and whether it is possible to calculate what, if any, savings it has provided for Americans,” Pallone wrote, according to his committee press release.

TrumpRx.gov and Its Savings Claims

TrumpRx.gov does not sell or dispense drugs, but instead directs users to coupons or links for discounts from participating drugmakers. The platform has been promoted as a way to lower cash prices on certain drugs, but its effectiveness and the accuracy of its savings claims are being called into question.

The White House first cited the $700 million figure in July. “TrumpRx.gov is a historic game changer for American patients,” White House spokesman Kush Desai told Fox Business, which first reported the figure. The administration repeated the claim in a Sept. 18 White House release on most-favored-nation pricing, saying the platform had delivered more than $700 million in savings and covered more than 1,000 brand-name and generic medicines. The release said GLP-1 drugs that once cost over $1,000 a month now start as low as $149, and that more than 500,000 eligible Medicare seniors paying $50 a month for GLP-1 drugs had saved $216 million.

Pallone’s letter to the GAO asks for an analysis of the platform’s tracking and savings calculations, including what data and methods support the $700 million figure. He also inquires about the number of transactions that have gone through TrumpRx, the number of users with private insurance, public insurance, or no insurance, and how many listed drugs are available more cheaply through insurance, generics, or manufacturer discount programs not shown on the site. Other questions ask which drugmaker agreements include provisions about TrumpRx and how the administration monitors patient safety problems tied to gaps in continuity of care.

Related Post: Site blocks users after policy update

Questions About Transparency and Accountability

Pallone’s broader complaint is about transparency. He said the administration has not disclosed key details of its most-favored-nation agreements with more than two dozen drugmakers, the deals that shape which discounts appear on TrumpRx. “There is no transparency into this process,” he said, arguing that the lack of disclosure makes it impossible to judge whether the site offers a meaningful financial benefit.

The White House has not released the details of how it calculated the savings, FactCheck.org reported in August. A spokesperson described the method only in general terms, as a comparison of what people paid through the site with what prior net prices would have been. Even taken at face value, $700 million would be less than 0.2% of the $467 billion spent on prescription drugs in the U.S. in 2024, according to the fact-checkers.

Use of the site was also limited early on. A KFF poll in March found that only 7% of regular prescription drug users had visited TrumpRx to compare prices in the month after launch, Pharmacy Times reported.

GAO Review and Next Steps

The site launched Feb. 5 with 43 brand-name drugs and added generics in May, bringing its generic listings to more than 600. The administration ties its prices to “most-favored-nation” agreements with 26 drugmakers, which it says cover 90% of the branded U.S. market.

GAO is Congress’s nonpartisan watchdog agency. It reviews how federal programs work and how they spend money, and it decides under its own procedures whether and when to take on a request. GAO had not publicly announced whether it would take up the request as of Oct. 30.